Healthleap has announced $38 million in total funding — TechCrunch reported the news on October 7, 2026. The startup, founded in 2022 in South Africa, builds an AI screening platform for hospitals. The $8 million seed round was co-led by Sequoia Capital and First Round Capital, while the $30 million Series A was led by Hummingbird Ventures. The company's valuation was not disclosed.
Funding details
The deal consists of two rounds. The first — an $8 million seed round — was co-led by Sequoia Capital and First Round Capital. The second — a $30 million Series A round — closed under the leadership of Hummingbird Ventures. The combined $38 million is the sum of both rounds. The company's valuation was not disclosed.
Notably, the number of hospitals running the Healthleap platform grew from three to more than fifty in a single year. The company's official press page also confirmed the $38 million funding announcement — a second source independent of the TechCrunch coverage. According to the company, its revenue grew more than tenfold over the same period.
How the platform works
The Healthleap system connects to a hospital's electronic health record (EHR) system. Language models then extract clinically important information from the written notes of doctors and nurses. This analysis is fed into risk models, and the result shows medical staff which patients need closer attention.
The platform's main task is early detection of patients who have no diagnosis yet but may belong to a risk group. For example, the system can rate a patient's risk of malnutrition or delirium as high based on signs in their records and send an alert to the physician.
The boundary is clearly defined: the software does not diagnose patients. It works only as a tool that helps doctors make decisions — the final conclusion always remains with the medical professional. This approach addresses questions of responsibility and safety in applying artificial intelligence in healthcare.
Today the platform screens for two conditions — malnutrition and delirium. Both can be detected through indirect signs in physicians' notes: for example, records of weight loss or notes about changes in consciousness. Language models combine exactly this kind of scattered data, assess the risk level, and show the medical worker which patient needs attention first.
This boundary is clearly defined by the company itself: the system does not issue a final conclusion about a patient's condition; it only directs the medical worker's attention to high-risk patients. In this approach, artificial intelligence is not the decision-maker but an assistive tool — the final decision always stays with the physician.
Startup history
Healthleap was founded by siblings Jemima and Josiah Meyer. The company began as a clinical nutrition tool created by Jemima for dietitians — it helped dietitians assess patients' nutritional status.
Later, the team decided to move from a narrow product to a general-purpose hospital platform. Today's Healthleap is a system integrated with electronic health records, capable of screening for multiple clinical conditions at once. The company now specializes in detecting malnutrition and delirium — a condition of sudden confusion in a patient.
The siblings' move from dietetics to a broad hospital platform is grounded in firsthand knowledge of clinical problems: the problem was first seen in one narrow area and then expanded into a general solution.
Customers and financial results
The platform is now deployed in more than 50 hospitals. The client list includes major US healthcare organizations — Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare. A year ago, there were only three customers.
The most concrete figure comes from the University of Pennsylvania hospital: Healthleap's malnutrition program delivered $23.8 million in annual financial benefit there. Of that, $6.3 million came from additional medical reimbursement, and $17.5 million from shorter patient hospital stays.
"At the University of Pennsylvania hospital, Healthleap's malnutrition program delivered $23.8 million in annual financial benefit." — TechCrunch
These figures demonstrate not only the clinical but also the economic effectiveness of AI screening tools: when patients spend less time in the hospital, hospital resources are saved and additional reimbursement opportunities open up. And the growth from three customers to more than fifty in a year shows the platform is being adopted at a fast practical pace.
